| [1] |
. Chin Bull Life Sci （生命科学），2006，18 （2）：161-167.
|
| [2] |
Meanwell NA. Improving drug design：an update on recent applications of efficiency metrics，strategies for replacing problematic elements，and compounds in nontraditional drug space［J］. Chem Res Toxicol，2016，29（4）：564-616.
|
| [3] |
Kanazawa J，Uchiyama M.Recent advances in the synthetic chemistry of bicyclo［1.1.1］pentane［J］. Synlett，2019，30（1）. doi：10.1055/s-0037-1610314.
|
| [4] |
Taylor RD，MacCoss M，Lawson ADG. Rings in drugs［J］. J Med Chem，2014，57（14）：5845-5859.
|
| [5] |
Meanwell NA. Synopsis of some recent tactical application of bioisosteres in drug design［J］. J Med Chem，2011，54（8）：2529-2591.
|
| [6] |
Pellicciari R，Raimondo M，Marinozzi M，et al. （S）-（+）-2-（3''-carboxybicyclo［1.1.1］pentyl）-glycine，a structurally new group I metabotropic glutamate receptor antagonist［J］. J Med Chem，1996，39（15）：2874-2876.
|
| [7] |
Filosa R，Marinozzi M，Costantino G，et al. Synthesis and biological evaluation of （2S）- and （2R）-2-（3''-phosphonobicyclo［1.1.1］pentyl）glycines as novel group III selective metabotropic glutamate receptor ligands［J］. Bioorg Med Chem，2006，14（11）：3811-3817.
|
| [8] |
Stepan AF，Subramanyam C，Efremov IV，et al. Application of the bicyclo［1.1.1］pentane motif as a nonclassical phenyl ring bioisostere in the design of a potent and orally active γ-secretase inhibitor［J］. J Med Chem，2012，55（7）：3414-3424.
|
| [9] |
Nicolaou KC，Vourloumis D，Totokotsopoulos S，et al. Synthesis and biopharmaceutical evaluation of imatinib analogues featuring unusual structural motifs［J］. ChemMedChem，2016，11（1）：31-37.
|
| [10] |
Thirumoorthi NT，Adsool VA. A practical metal-free homolytic aromatic alkylation protocol for the synthesis of 3-（pyrazin-2-yl）bicyclo［1.1.1］pentane-1-carboxylic acid［J］. Org Biomol Chem，2016，14（40）：9485-9489.
|
| [11] |
Measom ND，Down KD，Hirst DJ，et al. Investigation of a bicyclo［1.1.1］pentane as a phenyl replacement within an LpPLA2 inhibitor［J］. ACS Med Chem Lett，2017，8（1）：43-48.
|
| [12] |
Goh YL，Cui YT，Pendharkar V，et al. Toward resolving the resveratrol conundrum：synthesis and in vivo pharmacokinetic evaluation of BCP-resveratrol［J］. ACS Med Chem Lett，2017，8（5）：516-520.
|
| [13] |
Pu QL，Zhang HJ，Guo LQ，et al. Discovery of potent and orally available bicyclo［1.1.1］pentane-derived indoleamine-2，3-dioxygenase 1 （IDO1） inhibitors［J］. ACS Med Chem Lett，2020，11（8）：1548-1554.
|
| [14] |
St Jean DJJr，Fotsch C. Mitigating heterocycle metabolism in drug discovery［J］. J Med Chem，2012，55（13）：6002-6020.
|
| [15] |
Ishikawa M，Hashimoto Y. Improvement in aqueous solubility in small molecule drug discovery programs by disruption of molecular planarity and symmetry［J］. J Med Chem，2011，54（6）：1539-1554.
|
| [16] |
Auberson YP，Brocklehurst C，Furegati M，et al. Improving nonspecific binding and solubility：bicycloalkyl groups and cubanes as Para-phenyl bioisosteres［J］. ChemMedChem，2017，12（8）：590-598.
|
| [17] |
Kumar K，Woo SM，Siu T，et al. Cation-π interactions in protein–ligand binding：Theory and data-mining reveal different roles for lysine and arginine［J］. Chem Sci，2018，9（10）：2655-2665.
|
| [18] |
Makarov IS，Brocklehurst CE，Karaghiosoff K，et al. Synthesis of bicyclo［1.1.1］pentane bioisosteres of internal alkynes and Para -disubstituted benzenes from［1.1.1］propellane［J］. Angew Chem Int Ed，2017，56（41）：12774-12777.
|
| [19] |
Westphal MV，Wolfst?dter BT，Plancher JM，et al. Evaluation of tert-butyl isosteres：case studies of physicochemical and pharmacokinetic properties，efficacies，and activities［J］. Chem Med Chem，2015，10（3）：461-469.
|
| [20] |
Barbachyn MR，Hutchinson DK，Toops DS，et al. U-87947E，a protein quinolone antibacterial agent incorporating a bicyclo［1.1.1］pent-1-yl （BCP） subunit［J］. Bioorg Med Chem Lett，1993，3（4）：671-676.
|
| [21] |
Kung PP，Meng JJ. 2-Amino pyrimidine compounds as potent HSP-90 inhibitors：
US8080556［P］. 2011-12-20.
|
| [22] |
Hayashi K，Watanabe T，Toyama K，et al. Preparation of tricyclic heterocyclic compounds as JAK inhibitors：
WO2013024895［P］. 2013-02-21.
|
| [23] |
Richards N，Lewis R，Hamilton M，et al. Preparation of 1-［（4，
5-dihydro-1H-pyrazol-1-yl）carbonyl］bicyclo［
1.1.1］pentane derivatives as inhibitors of receptor interacting protein kinase for the treatment of disease：
WO2021062199［P］. 2021-04-01.
|
| [24] |
Su Y，Wang J，Bao R. Preparation of the inhibitor containing bicyclic derivative and their medical applications：
WO2020228756A1［P］. 2020-11-19.
|
| [25] |
Henderson JA，He M，Good AC，et al. Tricyclic compounds as degraders of Ikaros and Aiolos and their preparation：
WO2020210630A1［P］. 2020-10-15.
|
| [26] |
Soth MJ，Liu G，Le K，et al.
Bicyclo［
1.1.1］pentane inhibitors of dual leucine zipper （DLK） kinase for the treatment of disease：
US10428057［P］. 2019-10-01.
|
下载:
